Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2594 (LINC02594) is a member of the long non-coding RNA family, specifically classified as a long intergenic non-coding RNA (lincRNA). These are RNA molecules transcribed from genomic regions that do not overlap with known protein-coding genes and do not code for proteins themselves[1][3][5]. LINC02594 is also referred to as CTC-501O10.1, AC100830.4, and RP11-210K20.5[9]. While its specific biological functions have not been comprehensively defined, lincRNAs are generally involved in the regulation of gene expression—often by acting as molecular sponges for microRNAs or influencing chromatin structure and mRNA stability[3][5]. An upregulation of LINC02594 and its aliases has been reported in the plasma of gastric cancer patients, suggesting a potential role as a biomarker in this context[9]. There is currently insufficient evidence to classify LINC02594 as a direct therapeutic target or assign it specific interacting drugs or mechanisms of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2594 (LINC02594).